Treventis Corporation

TREVENTISTM Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine Common Conformational Morphology (CCM) to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimers disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform

Alzheimer's disease,parkinson's disease,als,protein misfolding diseases,drug discovery,and computer-aided drug design

Treventis corporation operates in the Biotechnology research industry.

Treventis corporation's revenue is 11m - 100m

Treventis corporation has 11 - 50 employees.